SPINK1 and posterior cortical atrophy: In a separate study using Cancer Outlier Profile Analysis (COPA), SPINK1 (serine peptidase inhibitor, Kazal type 1) was shown to be over‐expressed in ∼10–15% of the total PCa cases 4.